SPONSORED

Year in review: Cannabis laws in the U.S.

Majority favors legalization

•• 4 Min
Year in review: Cannabis laws in the U.S.

Although Congress failed to pass federal law to legalize cannabis in 2021, the push to end the federal ban on the ever-growing industry continues to gain momentum. While Republican lawmakers have traditionally opposed decriminalization, more and more people are starting to endorse or even introduce new cannabis laws. In addition, recent polls show that an estimated 68% of Americans are in favor of legalization, and many consumers now consider cannabis to be less dangerous than alcohol. Additionally, the industry's total addressable market has been predicted to grow to $ 84 billion by 2026.

Federal effort At the federal level, the Democrats have so far not been able to get enough cross-party support to prevent the threatened procrastination in the Senate. In 2021, neither the Cannabis Administration and Opportunity Act nor the Marijuana Opportunity Reinvestment and Expungement Act saw much progress. In addition, the SAFE Banking Act, which would have given cannabis companies access to commercial banking services, has so far failed in the Senate despite widespread support in the House of Representatives.

However, the Republican-led States Reform Act may offer Congress the most realistic chance at decriminalizing cannabis at the federal level. This "compromise" bill, tabled in November, would give states full power to regulate or ban cannabis as they see fit. As a result, cannabis would no longer be listed under the Controlled Substances Act, which would give cannabis companies access to commercial banking services. Additionally, the bill would allow the transportation of cannabis in interstate commerce and would likely also override Section 280E of the federal tax code, which currently prevents cannabis companies from applying for federal tax deductions. The bill would also allow cannabis companies to obtain loans and other aid from the Small Business Administration. Passing the States Reform Act would not legalize it at the federal level, but it would repeal many of the federal regulations that currently weigh on cannabis companies.

Additionally, a new bipartisan bill recently tabled in the House of Representatives aims to require the FDA to regulate hemp-derived CBD as a food and beverage ingredient. In the absence of clear federal guidelines regulating how much CBD from hemp can be added to a food or drink, this bill would give CBD companies clarity by requiring the FDA to finally come up with clear rules.

States are pushing forward Despite the failure of Congress to pass cannabis laws, the list of states allowing the legal use of cannabis by adults was expanded in 2021. New York, New Jersey, Connecticut, New Mexico, and Virginia are now on the list of states that allow recreational cannabis use. These 18 states make up nearly half of the US population. In addition, medical cannabis has been legalized in several more states, bringing the total to 36 states. On the other hand, the South Dakota Supreme Court has, on one rare occasion, overturned a state electoral initiative that voted for recreational cannabis legalization with 54% of the vote.

As for hemp products, states have also begun proposing and enacting laws to regulate the use of hemp in consumer products. For example, Governor Newsom recently passed California's A.B. 45 signed. This allows manufacturers to use hemp, hemp derivatives, cannabinoids (e.g. CBD) and extracts in food and beverages as well as in food supplements, cosmetics and even in animal feed.

Outlook for the year 2022 It is realistic that either the States Reform Act or the SAFE Banking Act will come into effect in 2022. The mid-term elections in 2022 will certainly affect whether and when either of the two bills will come into effect, but the lame duck period following the elections could offer hesitant legislators an attractive window of opportunity for bipartisan compromise. On the other hand, President Biden still appears to be against legalizing recreational cannabis, and it is unknown whether he would veto any of these bills.

Even if Congress doesn't act, states will begin to enact their own laws to ease the hurdles posed by the federal ban on cannabis companies. For example, lawmakers in New York, New Jersey, and Missouri recently tabled bills aimed at circumventing Section 280E of U.S. tax law by allowing cannabis companies to deduct business expenses from their state taxes. In addition, Michigan recently tabled a bill that would add to California's A.B. 45 and would allow the use of hemp-derived CBD in food and dietary supplements.

Even if federal legalization doesn't come in 2021, cannabis companies should continue to look out for new state regulations and also prepare for possible federal laws that would allow interstate trade, access to commercial banks, and federal tax deductions.

USAlegalization

Most Popular News

  1. SpaceX’s $8B Spectrum Deal Sends AT&T, Verizon, and T-Mobile Plummeting
  2. Is Project Vault Securing America’s Supply Chain or Squeezing It to the Breaking Point?
  3. Why Gautam Lohia Shifted from Global Consulting to Reboot a $20M Tech Micro-Cap
  4. Everyday Luxury, Unstoppable Scale: Aritzia Delivers 44% Net Revenue Growth
  5. Can Navy SEAL Leadership and Big Tech Scale Revolutionize Airborne Threat Detection?

Disclaimer


This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.